File: Attachment Asep NR Leadership Transition 21026_FINAL.pdf

Asep Medical Holdings Inc.

Asep Medical Holdings Inc. Announces Leadership Transition

Dr. Robert Hancock steps down as CEO and Chairman of Asep to focus on a more active scientific leadership role with the company's major operating businesses, Sepset Biosciences

and ABT Innovations

Vancouver, BC February 20, 2027 Asep Medical Holdings Inc. ("Asep" or the "Company") today announced that Dr. Robert Hancock has stepped down from his roles as Chief Executive Officer and Chairman of the Board to focus more directly on advancing the Company's scientific initiatives. Dr. Hancock will intensify his role as Chief Executive Officer in both Sepset Biosciences Inc. and ABT Innovations Inc., of which Asep is the major shareholder, where he will focus on bringing products to market, and driving research, development, intellectual property and scientific strategy.

Dr. Hancock took over as CEO and Chairman of Asep on July 5, 2022, following the departure of former CEO Rudy Mazzocchi, who stepped down for health reasons. Over the past four years, Dr. Hancock has provided steady and visionary leadership, guiding Asep through key stages of growth and positioning the Company at the forefront of rapid diagnostic and therapeutic innovations targeting sepsis and antibiotic resistance.

The Board of Directors extends its sincere gratitude to Dr. Hancock for his dedication and leadership during this important period. "Dr. Hancock's vision and scientific expertise have been instrumental in advancing Asep's mission," said Board spokesperson, Dr. Richard Heinzl. "We are deeply appreciative of his commitment and are pleased he will continue to lead the development of both our sepsis diagnostic and our anti-biofilm technologies."

Board member Mr. Derrold Norgaard commented, "We think this is a great opportunity to sharpen our focus-- leveraging Dr. Hancock's world-class scientific leadership within our operating businesses while we seek a CEO with deep biosciences expertise and strong North American capital markets connections to guide Asep through its next phase of growth."

The Board has initiated a search for a new Chief Executive Officer and Chairman. The Company is seeking a biosciences leader with demonstrated capital markets experience and established relationships, across North Asep Medical Holdings Inc.

American and globally, to support Asep's strategic and financing objectives.

Asep remains committed to delivering innovative solutions to address significant unmet medical needs and looks forward to this next chapter of focused scientific advancement and corporate growth.

ABOUT ASEP MEDICAL HOLDINGS INC. Asep is a standout biotechnology research and development company based in Victoria, BC, Canada. The Company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Robert E. W. Hancock, one of the world's foremost microbiologists and the former CEO of Asep. Asep is the major shareholder of two private research and development companies -- Sepset Biosciences (developing Asep's leading product, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the Company's patented innovations address unmet medical needs, it presents a unique investment opportunity for both retail and institutional investors.

FOR MORE INFORMATION, PLEASE CONTACT Chris Dallin Asep Medical Holdings Inc. E. chris@asepmedical.com T. 604-362-3654